Radius Health, Inc. (RDUS): Price and Financial Metrics


Radius Health, Inc. (RDUS): $5.93

-0.11 (-1.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RDUS POWR Grades


  • RDUS scores best on the Growth dimension, with a Growth rank ahead of 94.99% of US stocks.
  • The strongest trend for RDUS is in Growth, which has been heading up over the past 179 days.
  • RDUS's current lowest rank is in the Sentiment metric (where it is better than 1.38% of US stocks).

RDUS Stock Summary

  • Radius Health Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.23% of US listed stocks.
  • RDUS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.91% of US stocks.
  • In terms of volatility of its share price, RDUS is more volatile than 92.32% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Radius Health Inc, a group of peers worth examining would be INFN, INSM, KPTI, KMPH, and ALBO.
  • RDUS's SEC filings can be seen here. And to visit Radius Health Inc's official web site, go to www.radiuspharm.com.

RDUS Valuation Summary

  • In comparison to the median Healthcare stock, RDUS's EV/EBIT ratio is 183.28% lower, now standing at -24.4.
  • RDUS's price/earnings ratio has moved down 10.9 over the prior 88 months.
  • Over the past 88 months, RDUS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RDUS.

Stock Date P/S P/B P/E EV/EBIT
RDUS 2021-08-31 2.6 -2.9 -10.9 -24.4
RDUS 2021-08-30 2.6 -2.8 -10.7 -24.1
RDUS 2021-08-27 2.6 -2.8 -10.7 -24.1
RDUS 2021-08-26 2.5 -2.8 -10.4 -23.6
RDUS 2021-08-25 2.6 -2.8 -10.6 -23.9
RDUS 2021-08-24 2.6 -2.8 -10.7 -24.1

RDUS Growth Metrics

    The 5 year net income to common stockholders growth rate now stands at -2.37%.
  • Its year over year revenue growth rate is now at 29.04%.
  • Its year over year net income to common stockholders growth rate is now at 31.73%.
Over the past 18 months, RDUS's revenue has gone up $29,506,000.

The table below shows RDUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 229.973 -22.434 -70.176
2021-09-30 227.651 -51.543 -75.977
2021-06-30 248.667 -61.983 -60.233
2021-03-31 246.983 -59.876 -87.303
2020-12-31 238.645 -73.948 -109.208
2020-09-30 231.527 -54.003 -112.538

RDUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RDUS has a Quality Grade of C, ranking ahead of 69.93% of graded US stocks.
  • RDUS's asset turnover comes in at 1.266 -- ranking 15th of 682 Pharmaceutical Products stocks.
  • FOLD, ADMS, and CSBR are the stocks whose asset turnover ratios are most correlated with RDUS.

The table below shows RDUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.266 0.929 -0.122
2021-03-31 1.287 0.930 -0.218
2020-12-31 1.249 0.928 -0.297
2020-09-30 1.170 0.926 -0.307
2020-06-30 0.974 0.914 -0.387
2020-03-31 0.858 0.912 -0.347

RDUS Price Target

For more insight on analysts targets of RDUS, see our RDUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.14 Average Broker Recommendation 1.93 (Hold)

RDUS Stock Price Chart Interactive Chart >

Price chart for RDUS

RDUS Price/Volume Stats

Current price $5.93 52-week high $23.00
Prev. close $6.04 52-week low $4.97
Day low $5.75 Volume 720,200
Day high $5.99 Avg. volume 918,563
50-day MA $7.49 Dividend yield N/A
200-day MA $10.79 Market Cap 282.09M

Radius Health, Inc. (RDUS) Company Bio


Radius Health is a biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. The company was founded in 2003 and is based in Waltham, Massachusetts.


RDUS Latest News Stream


Event/Time News Detail
Loading, please wait...

RDUS Latest Social Stream


Loading social stream, please wait...

View Full RDUS Social Stream

Latest RDUS News From Around the Web

Below are the latest news stories about Radius Health Inc that investors may wish to consider to help them evaluate RDUS as an investment opportunity.

Radius Health, Inc. 2022 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Radius Health, Inc. in conjunction with their 2022 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates

Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Radius Health, Inc. Fourth Quarter & Full Year 2021 Results

Q4 2021 TYMLOS® net revenue of $65 million vs. $60 million in Q4 2020, up 9%This is a record quarter – over 18 quarters – since the launch in May 2017FY 2021 TYMLOS Net Revenue of $219 vs. $208 million in FY 2020, up 5%Net Loss reduced by ~36%: ($70) million FY 2021 vs ($109) million FY 2020Adjusted EBITDA (Non-GAAP) loss reduced by ~56%: ($24) million FY 2021 vs. ($54) million FY 2020FY 2022 financial objectives: $232 million TYMLOS Net RevenueIncorporate seasonality of Net Revenue: ~42% in 1H

Yahoo | February 24, 2022

Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022

BOSTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and provide a company update. Conference Call Information:Domestic Dial-In Number: 1 (866) 323-7965International Dial-In Number: 1 (346) 406-0961Conference ID: 7696052Webcast Link: https://edge.me

Yahoo | February 15, 2022

Read More 'RDUS' Stories Here

RDUS Price Returns

1-mo -17.75%
3-mo -27.24%
6-mo -64.13%
1-year -69.85%
3-year -71.91%
5-year -83.02%
YTD -14.31%
2021 -61.25%
2020 -11.41%
2019 22.26%
2018 -48.10%
2017 -16.46%

Continue Researching RDUS

Want to see what other sources are saying about Radius Health Inc's financials and stock price? Try the links below:

Radius Health Inc (RDUS) Stock Price | Nasdaq
Radius Health Inc (RDUS) Stock Quote, History and News - Yahoo Finance
Radius Health Inc (RDUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6084 seconds.